Skip to main content
. Author manuscript; available in PMC: 2021 Jun 8.
Published in final edited form as: Cancer Immunol Res. 2019 Feb 19;7(4):683–692. doi: 10.1158/2326-6066.CIR-18-0748

Figure 6.

Figure 6.

CD123.IL7Ra T cells have improved expansion and in vivo antileukemia control. A, T cells were transduced with ffLuc to enable tracking of expansion and persistence versus unlabeled MV-4–11. (n = 5 mice each group, one T-cell donor used for cohort; solid line, mean; dotted lines, individual mice). B, Kaplan-Meier survival analysis, median survival: CLEC12A-ENG, 56 days; CLEC12A-ENG.CD123IL7Ra, undefined. (**, P<0.01). C, Representative images of mice.